Millendo braces for deep cuts after its last clinical effort ends in defeat and a last search for a way to end things
Turn out the lights, the party is over at Millendo Therapeutics.
Nine months after pulling the plug on a pivotal study of their lead drug, the Ann Arbor, MI-based biotech is shuttering its sole remaining early-stage study for their NK3R antagonist MLE-301. And they’re sounding a bleak note, planning some deep cuts for the remaining staff while the board goes about the business of finding a way to gain some value out of this for shareholders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.